Taysha Gene Therapies Plots $200M Stock Sale as Shares Drop in Pre-Market Trade
Taysha Gene Therapies (TSHA) saw its shares decline 13% in pre-market trading after announcing a priced underwritten public offering totaling 32,500,001 common shares and 833,333 pre-funded warrants. The offering, which is expected to generate roughly $200.0 million in gross proceeds before fees and expenses, is scheduled to close on or about June …